PI Industries Limited (PIIND)
Transcript of the Earnings Conference Call pertaining to the Unaudited Financial Results for the quarter ended June 30, 2026
AI summary
- Q1 FY27 revenue Rs 17,023 million; gross margin 57%, EBITDA margin 22%
- Domestic agrochem volume grew 12%, biologicals up 50% with 3-year CAGR 15%
- Export business challenged by global industry downturn; recovery expected H2 FY27
- Pharma CRDMO business in early stage; long gestation with investments ongoing
- New molecule pipeline includes ~90 projects; 4-5 product launches planned in FY27
- Pioxaniliprole insecticide launch expected in India within FY27; global launches later
- Biological nematicide registered in Brazil, Mexico, US; unique foliar application
- Capex guidance Rs 700-800 crore for FY27; investments in manufacturing and innovation
- Net working capital reduced by 19 days, releasing Rs 300 crore cash; net cash Rs 38 billion
- Management confident on medium-term growth despite near-term pricing pressures
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PIIND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PIIND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on PI Industries Limited
Important.
The summary above is generated automatically from PI Industries Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.